Several studies have shown that angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are useful in the treatment of hypertension, cardiovascular disease, chronic heart failure, and some types of nephropathy. In this context, dual renin-angiotensin system blockade with both angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers may be more effective than treatment with each agent alone. Many clinical trials have demonstrated the beneficial effect of this combined treatment on proteinuria, hypertension, heart failure, and cardiovascular events. Moreover, these studies demonstrated that dual renin-angiotensin system blockade is generally safe and well tolerated. Long-term studies are under way to confirm these effects and also investigate the effectiveness of dual reninangiotensin system blockade on cerebrovascular disease and prevention of type 2 diabetes mellitus. These studies are expected to define the optimal use of combination treatment in everyday clinical practice. This review considers the most important clinical trials that evaluated the effect of dual renin-angiotensin system blockade on blood pressure, heart failure, and renal function.
Gavras I.Bradykinin-mediated effects of ACE inhibition. Kidney Int42:1020–1029, 1992
2.
Linz W, Wiemer G, Gohlke P, et al. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev47:25–49, 1995
3.
Juillerat L, Nussberger J, Menard J, et al. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension16:564–572, 1990
4.
Roig E, Perez-Villa F, Morales M, et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J21:53–57, 2000
5.
Azizi M, Ménard J.Combined blockade of the reninangiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation109:2492–2499, 2004
6.
Dzau VJ. Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: A unifying hypothesis. Hypertension37:1047–1052, 2001
7.
Neutel JM. Effect of the renin-angiotensin system on the vessel wall: Using ACE inhibition to improve endothelial function. J Hum Hypertens18:599–606, 2004
8.
Kasiske BL, Ma JZ, Kalil RS, et al. Effects of antihypertensive therapy on serum lipids. Ann Intern Med122:133–141, 1995
9.
McFarlane SI, Kumar A, Sowers JR. Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol91:30–37, 2003
10.
Kranzhofer R, Schmidt J, Pfeiffer CA, et al. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol19:1623–1629, 1999
11.
van Leeuwen RT, Kol A, Andreotti F, et al. Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation90:362–368, 1994
12.
Papadakis JA, Mikhailidis DP, Vrentzos GE, et al. Effect of antihypertensive treatment on plasma fibrinogen and serum HDL levels in patients with essential hypertension. Clin Appl Thromb Hemost11:139–146, 2005
13.
Athyros VG, Mikhailidis DP, Papageorgiou AA, et al; GREACE Study Collaborative Group. Relationship between LDL-C and non-HDL-C levels and clinical out-come in the GREek Atorvastatin and Coronary-heart-dis-ease Evaluation (GREACE) Study. Curr Med Res Opin20:1385–1392, 2004
14.
Ganotakis ES, Papadakis JA, Vrentzos GE, et al. The effects of antihypertensive therapy on haemostatic parameters. Curr Pharm Des9:2445–2464, 2003
15.
Papadakis JA, Ganotakis ES, Jagroop IA, et al. Effect of hypertension and its treatment on lipid, lipoprotein (a), fibrinogen, and bilirubin levels in patients referred for dyslipidemia. Am J Hypertens12:673–681, 1999
16.
Lever AF, Hole DJ, Gillis CR, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?Lancet352:179–184, 1998
17.
Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy: The Collaborative Study Group. N Engl J Med329:1456–1462, 1993
18.
Brenner BM, Cooper ME, de Zeeuw D, et al; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med345:861–869, 2001
19.
Arima S.Role of angiotensin II and endogenous vasodilators in the control of glomerular hemodynamics. Clin Exp Nephrol7:172–178, 2003
20.
Ennezat PV, Berlowitz M, Sonnenblick EH, Le Jemtel TH. Therapeutic implications of escape from angiontensin-converting enzyme inhibition in patients with chronic heart failure. Curr Cardiol Rep2:258–262, 2000
21.
Palmer BF. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: What to do if the serum creatinine and/or serum potassium concentration rises. Nephrol Dial Transplant18:1973–1975, 2003
22.
Weir MR, Weber MA, Neutel JM, et al. Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: A clinical experience trial. ACTION Study Investigators. Am J Hypertens14:567–572, 2001
23.
McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation100:1056–1064, 1999
24.
Cohn JN, Tognoni G, Glazer R, et al. Baseline demo-graphics of the Valsartan Heart Failure Trial. Val-HeFT Investigators. Eur J Heart Fail2:439–446, 2000
25.
Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med345:1667–1675, 2001
26.
McMurray JJ, Ostergren J, Swedberg K, et al; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial. Lancet362:767–771, 2003
27.
Pfeffer MA, McMurray JJ, Velazquez EJ, et al; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med349:1893–1906, 2003
28.
Marathias KP, Agroyannis B, Mavromoustakos T, et al. Hematocrit-lowering effect following inactivation of renin-angiotensin system with angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Curr Top Med Chem4:483–486, 2004
29.
Freudenthaler SM, Schreeb K, Korner T, et al. Angiotensin II increases erythropoietin production in healthy human volunteers. Eur J Clin Invest29:816–823, 1999
30.
Jacobsen P, Andersen S, Rossing K, et al. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int63:1874–1880, 2003
31.
Finnegan PM, Gleason BL. Combination ACE inhibitors and angiotensin II receptor blockers for hypertension. Ann Pharmacother37:886–889, 2003
32.
Azizi M, Chatellier G, Guyene TT, et al. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation92:825–834, 1995
33.
Azizi M, Guyene TT, Chatellier G, et al. Additive effects of losartan and enalapril on blood pressure and plasma active renin. Hypertension29:634–640, 1997
34.
Azizi M, Linhart A, Alexander J, et al. Pilot study of combined blockade of the renin-angiotensin system in essential hypertensive patients. J Hypertens18:1139–1147, 2000
35.
Weir MR, Smith DH, Neutel JM, et al. Valsartan alone or with a diuretic or ACE inhibitor as treatment for African American hypertensives: relation to salt intake. Am J Hypertens14:665–671, 2001
36.
Forclaz A, Maillard M, Nussberger J, et al. Angiotensin II receptor blockade: Is there truly a benefit of adding an ACE inhibitor?Hypertension41:31–36, 2003
37.
Morgan T, Anderson A, Bertram D, et al. Effect of candesartan and lisinopril alone and in combination on blood pressure and microalbuminuria. J Renin Angiotensin Aldosterone Syst5:64–71, 2004
38.
Gaudio G, Guasti L, Schizzarotto A, et al.Changes in plasma lipids during renin-angiotensin system blockade by combination therapy (enalapril plus valsartan) in patients with diabetes and hypertension. J Cardiovasc Pharmacol45:362–366, 2005
39.
Waeber B, Aschwanden R, Sadecky L, et al. Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone. J Hypertens19:2097–2104, 2001
40.
Anan F, Takahashi N, Ooie T, et al. Effects of valsartan and perindopril combination therapy on left ventricular hypertrophy and aortic arterial stiffness in patients with essential hypertension. Eur J Clin Pharmacol61:353–359, 2005
41.
Suzuki H, Kanno Y, Kaneko K, et al. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy. Ther Apher Dial8:320–327, 2004
42.
Pitt B, Segal R, Martinez FA, Meurers G, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)Lancet349:747–752, 1997
43.
Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet355:1582–1587, 2000
44.
Epstein BJ, Gums JG. Angiotensin receptor blockers versus ACE inhibitors: Prevention of death and myocardial infarction in high-risk populations. Ann Pharmacother39:470–480, 2005
45.
Cruden NL, Newby DE. Angiotensin antagonism in patients with heart failure: ACE inhibitors, angiotensin receptor antagonists or both?Am J Cardiovasc Drugs4:345–353, 2004
Hebert PR, Foody JM, Hennekens CH. The reninangiotensin system: The role of inhibitors, blockers, and genetic polymorphisms in the treatment and prevention of heart failure. Curr Vasc Pharmacol1:33–39, 2003
48.
Yasumura Y, Miyatake K, Okamoto H, et al. Rationale for the use of combination angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker therapy in heart failure. Circ J68:361–366, 2004
49.
Fabi MR, Teerlink JR. The addition of angiotensin receptor blockers to angiotensin-converting enzyme inhibitors-What has time told us?Curr Heart Fail Rep2:59–64, 2005
50.
Mielniczuk L, Stevenson LW. Angiotensin-converting enzyme inhibitors and angiotensin II type I receptor blockers in the management of congestive heart failure patients: what have we learned from recent clinical trials?Curr Opin Cardiol20:250–255, 2005
51.
Wong M, Staszewsky L, Latini R, et al; Val-HeFT Heart Failure Trial Investigators. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol40:970–975, 2002
52.
Carson P, Tognoni G, Cohn JN. Effect of Valsartan on hospitalization: Results from Val-HeFT. J Card Fail9:164–171, 2003
53.
Cohn JN, Anand IS, Latini R, et al; Valsartan Heart Failure Trial Investigators. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: Results from the Valsartan Heart Failure Trial. Circulation108:1306–1309, 2003
54.
Anand IS, Fisher LD, Chiang YT, et al; Val-HeFT Investigators. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation107:1278–1283, 2003
55.
Hamroff G, Katz SD, Mancini D, et al. Addition of angiotensin II receptor blockade to maximal angiotensinconverting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation99:990–992, 1999
56.
Baruch L, Anand I, Cohen IS, et al. Augmented short-and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group. Circulation99:2658–2664, 1999
57.
Young JB, Dunlap ME, Pfeffer MA, et al; Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Investigators and Committees. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation110:2618–2626, 2004
58.
Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet360:752–760, 2002
59.
Nakamura Y, Yoshiyama M, Omura T, et al. Beneficial effects of combination of ACE inhibitor and angiotensin II type 1 receptor blocker on cardiac remodeling in rat ardial infarction. Cardiovasc Res57:48–54, 2003
60.
Kitakaze M, Asanuma H, Funaya H, et al. Angiotensinconverting enzyme inhibitors and angiotensin II receptor blockers synergistically increase coronary blood flow in canine ischemic myocardium: role of bradykinin. J Am Coll Cardiol40:162–166, 2002
61.
Weidenbach R, Schulz R, Gres P, et al. Enhanced reduction of myocardial infarct size by combined ACE inhibition and AT(1)-receptor antagonism. Br J Pharmacol131:138–144, 2000
62.
Di Pasquale P, Bucca V, Scalzo S, et al. Does the addition of losartan improve the beneficial effects of ACE inhibitors in patients with anterior myocardial infarction? A pilot study. Heart81:606–611, 1999
63.
Jacobsen P, Parving HH. Beneficial impact on cardiovascular risk factors by dual blockade of the reninangiotensin system in diabetic nephropathy. Kidney Int Suppl92:S108-S110, 2004
64.
Yusuf S.From the HOPE to the ONTARGET and the TRANSCEND studies: Challenges in improving prognosis. Am J Cardiol89:18–25, 2002
Swedberg K, Cleland J, Dargie H, et al. The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology: Guidelines for the diagnosis and treatment of chronic heart failure: Executive summary (update 2005). Eur Heart J26: 1115–1140, 2005
67.
Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: Summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol46:1116–1143, 2005
68.
Pitt B, Zannad F, Remme WJ, et al, for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med341:709–717, 1999
69.
Luno J, Praga M, de Vinuesa SG. The reno-protective effect of the dual blockade of the renin angiotensin system (RAS). Curr Pharm Des11:1291–1300, 2005
70.
Brewster UC, Perazella MA. Can dual blockade of the renin-angiotensin system reduce progression of kidney disease beyond monotherapy?Expert Opin Drug Saf3:9–23, 2004
71.
Hilgers KF, Dotsch J, Rascher W, et al. Treatment strategies in patients with chronic renal disease: ACE inhibitors, angiotensin receptor antagonists, or both?Pediatr Nephrol19:956–961, 2004
72.
Wade VL, Gleason BL. Dual blockade of the reninangiotensin system in diabetic nephropathy. Ann Pharmacother38:1278–1282, 2004
73.
Nakao N, Seno H, Kasuga H, et al. Dual blockade of the renin-angiotensin system in chronic renal disease: To do or not to do. Clin Exp Nephrol8:183–187, 2004
74.
Wolf G, Ritz E.Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: Pathophysiology and indications. Kidney Int67:799–812, 2005
75.
Codreanu I, Perico N, Remuzzi G.Dual blockade of the rennin-angiotensin system: The ultimate treatment for renal protection?J Am Soc Nephrol16 (Suppl 1):S34-S38, 2005
76.
Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet361:117–124, 2003
77.
Nakao N, Seno H, Kasuga H, et al. Effects of combination treatment with losartan and trandolapril on office and ambulatory blood pressures in non-diabetic renal disease: A COOPERATE-ABP substudy. Am J Nephrol24:543–548, 2004
78.
Zoccali C, Valvo E, Russo D, et al. Antiproteinuric effect of losartan in patients with chronic renal diseases. Nephrol Dial Transplant12:234–235, 1997
79.
Ruilope LM, Aldigier JC, Ponticelli C, et al. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. J Hypertens18:89–95, 2000
80.
Kincaid-Smith P, Fairley K, Packham D.Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria. Nephrol Dial Transplant17:597–601, 2002
81.
Luno J, Barrio V, Goicoechea MA, et al. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies. Kidney Int62:47–52, 2002
82.
Jacobsen P, Andersen S, Jensen BR, et al. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol14:992–999, 2003
83.
Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study. BMJ321:1440–1444, 2000
84.
Russo D, Minutolo R, Pisani A, et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis38:18–25, 2001
85.
Campbell R, Sangalli F, Perticucci E, et al. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int63:1094–1103, 2003
86.
Laverman GD, Navis G, Henning RH, et al. Dual reninangiotensin system blockade at optimal doses for protein-uria. Kidney Int62:1020–1025, 2002
87.
Rutkowski P, Tylicki L, Renke M, et al. Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis. Am J Kidney Dis43:260–268, 2004
88.
Rossing K, Jacobsen P, Pietraszek L, et al. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: A randomized double-blind crossover trial. Diabetes Care26:2268–2274, 2003
89.
Song JH, Lee SW, Suh JH, et al. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy. Clin Nephrol60:318–326, 2003
90.
Segura J, Praga M, Campo C, et al. Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses. J Renin Angiotensin Aldosterone Syst4:43–47, 2003
91.
Vogt L, Navis G, de Zeeuw D.Individual titration for maximal blockade of the renin-angiotensin system in proteinuric patients: A feasible strategy?J Am Soc Nephrol16:53–57, 2005
92.
Renke M, Tylicki L, Rutkowski P, et al. Low-dose angiotensin II receptor antagonists and angiotensin II-converting enzyme inhibitors alone or in combination for treatment of primary glomerulonephritis. Scand J Urol Nephrol38:427–433, 2004
93.
Horita Y, Tadokoro M, Taura K, et al. Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin A nephropathy. Hypertens Res27:963–970, 2004
94.
Homma K, Hayashi K, Kanda T, et al. Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease. J Hum Hypertens18:879–884, 2004
95.
Cetinkaya R, Odabas AR, Selcuk Y.Anti-proteinuric effects of combination therapy with enalapril and losartan in patients with nephropathy due to type 2 diabetes. Int J Clin Pract58:432–435, 2004
96.
Fujisawa T, Ikegami H, Ono M, et al. Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy. Am J Hypertens18:13–17, 2005
97.
Griffin KA, Abu-Amarah I, Picken M, et al. Renoprotection by ACE inhibition or aldosterone blockade is blood pressure-dependent. Hypertension41:201–206, 2003
98.
Bidani AK, Griffin KA, Bakris G, et al. Lack of evidence of blood pressure-independent protection by reninangiotensin system blockade after renal ablation. Kidney Int57:1651–1661, 2000
99.
Dillon JJ. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for IgA nephropathy. Semin Nephrol24:218–224, 2004
100.
Andersen NH, Mogensen CE. Dual blockade of the renin angiotensin system in diabetic and nondiabetic kidney disease. Curr Hypertens Rep6:369–376, 2004
101.
Cooper M, Boner G.Dual blockade of the reninangiotensin system in diabetic nephropathy. Diabet Med21:15–18, 2004
Hebert LA, Falkenhain ME, Nahman NS Jr, et al. Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy. Am J Nephrol19:1–6, 1999
104.
Tutuncu NB, Gurlek A, Gedik O.Efficacy of ACE inhibitors and ATII receptor blockers in patients with microalbuminuria: A prospective study. Acta Diabetol38:157–161, 2001
105.
Liberopoulos EN, Mikhailidis DP, Elisaf MS. Diagnosis and management of the metabolic syndrome in obesity. Obes Rev6:283-296, 2005
106.
The PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet358:1033–1041, 2001
107.
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA288:2981–2997, 2002
108.
Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet353:611–616, 1999
109.
Dahlof B, Devereux RB, Kjeldsen SE, et al; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For End point reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet359:995–1003, 2002
110.
Lithell H, Hansson L, Skoog I, et al; SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial. J Hypertens21:875–886, 2003
111.
Schrader J, Luders S, Kulschewski A, et al; the Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS study: Evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke34:1699–1703, 2003
112.
Fournier A, Messerli FH, Achard JM, et al. Cerebroprotection mediated by angiotensin II: A hypothesis supported by recent randomized clinical trials. J Am Coll Cardiol43:1343–1347, 2004
113.
Schmidt R, Fazekas F, Enzinger C, et al. Risk factors and progression of small vessel disease-related cerebral abnormalities. J Neural Transm Suppl62:47–52, 2002
114.
Unger T.Inhibiting renin-angiotensin in the brain: The possible therapeutic implications. Blood Press10:12–16, 2001
115.
Yusuf S, Sleight P, Pogue J, et al; the Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med342:145–153, 2000
116.
Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet363:2022–2031, 2004
117.
Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab30:487–496, 2004
118.
Liberopoulos EN, Tsouli S, Mikhailidis DP, et al. Preventing type 2 diabetes in high risk patients: An overview of lifestyle and pharmacological measures. Curr Drug Targets7:in press, 2006
119.
Khan MA, Morgan RJ, Mikhailidis DP. The choice of antihypertensive drugs in patients with erectile dysfunction. Curr Med Res Opin18:103–107, 2002
120.
Becker AJ, Uckert S, Stief CG, et al. Plasma levels of angiotensin II during different penile conditions in the cavernous and systemic blood of healthy men and patients with erectile dysfunction. Urology58:805–810, 2001
121.
Becker AJ, Uckert S, Stief CG, et al. Possible role of bradykinin and angiotensin II in the regulation of penile erection and detumescence. Urology57:193–198, 2001
122.
Ando H, Furugori K, Shibata D, et al. Dual reninangiotensin blockade therapy in patients at high risk of early ovarian hyperstimulation syndrome receiving IVF and elective embryo cryopreservation: a case series. Hum Reprod18:1219–1222, 2003
123.
Athyros VG, Mikhailidis DP, Papageorgiou AA, et al; GREACE Study Collaborative Group. Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. J Hum Hypertens18:781–788, 2004
